Issue 19 - The Cancer Letter

<img class="lazy" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://cdn.cancerletter.com/media/2021/03/17053004/TCL-logo-horizontal-white.png" alt="" >

Vol.

33

No.

19

May 18, 2007May 18, 2007

Free

DOWNLOAD THE PDF

After ODAC: Questions On ESA Claims, Advertising, Reimbursement Gain Urgency.

Amgen Claimed QOL Benefit Despite FDA Label Change.

“Miracle-Gro for Cancer?” ODAC Members Vent At Amgen And J&J Over Claims, Advertising.

FDA Begins To Examine Its Role In Allowing Misleading Consumer Advertising.

CMS Proposal To Limit ESA Use Is Too Much, Too Fast, Critics Say.

Recent Issues

Volume 52 | Issue 23 - June 12, 2026

Volume 52 | Issue 22 - June 05, 2026

Volume 52 | Issue 21 - May 29, 2026

Volume 52 | Issue 20 - May 22, 2026

Volume 52 | Issue 19 - May 15, 2026

Volume 52 | Issue 18 - May 08, 2026